
Opinion|Videos|February 27, 2025
Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer
Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- How can we optimize HER2 testing and antibody-drug conjugate treatment selection considering tumor heterogeneity across different cancer sites?
- Are there additional biomarkers beyond HER2 that can help guide mBC therapy selection?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5



























